ReviewNPJ breast cancer2025
Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration.
Review in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Pan-cancer prioritization of CCDC69 reveals an immune-enriched and therapeutically sensitive breast cancer phenotype.Discover oncology · 2026Article
- The role of the WD40-repeat protein family in cancer.Molecular cancer · 2026Review
- Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- An overview of the DNA damage response in female reproductive system and breast cancers: A narrative review.International journal of reproductive biomedicine · 2026Review
- Precision immunotherapy for breast cancer: from biomarkers to clinical practice.Cancer biology & medicine · 2026Article
- Comprehensive Overview of Gastric Cancer Immunohistochemistry: Key Biomarkers, Advanced Detection Methods, and Perspectives.Medicina (Kaunas, Lithuania) · 2026Review
- Host-microbiome interactions in breast cancer progression and treatment response.Frontiers in medicine · 2026Review
- Peripheral blood biomarkers in PD-1/PD-L1 immunotherapy: distinguishing predictive from prognostic biomarkers.Frontiers in immunology · 2026Review
- Immune evasion driven by lipid metabolic reprogramming in endocrine-resistant HRFrontiers in immunology · 2026Review
- B cell-mediated immune surveillance defines the favorable prognosis of occult breast cancer: a multi-omics study.Frontiers in immunology · 2026Article
- Immune Checkpoint Inhibitors in Breast Cancer: Mechanisms, Biomarkers, and Future Therapeutic Strategies.Therapeutics and clinical risk management · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has redefined treatment paradigms across several malignancies, yet its application in breast cancer remains limited to select subtypes, particularly triple-negative breast cancer. As immune checkpoint inhibitors advance into earlier disease stages and broader clinical use, the identification of predictive biomarkers is essential to optimize patient selection and therapeutic outcomes. This review critically examines the current landscape of immunotherapy biomarkers in breast cancer and discusses their predictive value across breast cancer subtypes and treatment settings, highlighting both their clinical relevance and limitations. While conventional single biomarkers have demonstrated clinical relevance, they remain limited in sensitivity and specificity. Recent data suggest that gene expression signatures may offer superior predictive power. Moreover, emerging evidence supports the utility of integrated, multi-parametric biomarker strategies that combine genomic, transcriptomic, spatial, and dynamic immune profiling. Ongoing endeavors in standardization, validation, and the incorporation of artificial intelligence-driven analytics are critical to translating these biomarkers into precision immuno-oncology for breast cancer.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.